NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
LOS ANGELES, Feb. 11, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that Christopher DeGiorgio , M.D., Vice President of Neurology at NeuroSigma and Professor of Neurology at the University of California, Los Angeles (UCLA), and Colin Kealey , M.D., Manager of Business Development at NeuroSigma, will present in London, an overview of external trigeminal nerve stimulation (eTNS™) for the treatment of epilepsy and depression at The Royal Society of Medicine's Sixth Medical Innovations Summit on February 16, 2013.
Now available in the European Union, with a physician's prescription, the Monarch™ eTNS™ System consists of a small stimulator that can be placed in a pocket or worn at the waist, and an electric patch that is placed on the forehead. The patch stimulates the trigeminal nerve through the surface of the skin, and is used primarily while the patient is asleep.
A Phase II randomized controlled clinical trial, conducted at UCLA and the University of Southern California (USC), for the use of eTNS™ for the treatment of drug-resistant epilepsy showed a robust effect on seizure frequency and mood. At the end of the eighteen week treatment period, more than 40% of patients experienced a greater than 50% reduction in seizure frequency when using the device, as recently reported in the January 30, 2013 on-line issue of Neurology®.